Measurement uncertainty for serum free light chain assays: Estimation and implication on result interpretation

Clinical Biochemistry

Volumn 46, Issue 4-5, 2013, Pages 381-384

  Wang, Li ^a   Chan, Pak Cheung R ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Measurement uncertainty; Monoclonal gammopathy; Reference change value; Serum free light chain assays

Indexed keywords

ANALYTICAL PARAMETERS; ARTICLE; ASSAY; DISEASE ACTIVITY; INFORMATION PROCESSING; LASER NEPHELOMETER; MEASUREMENT UNCERTAINTY; MONOCLONAL IMMUNOGLOBULINEMIA; PRIORITY JOURNAL; REFERENCE CHANGE VALUE; REFERENCE VALUE; RETROSPECTIVE STUDY; SERUM FREE LIGHT CHAIN ASSAY; SYSTEMATIC ERROR;

BLOOD CHEMICAL ANALYSIS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; PARAPROTEINEMIAS; QUALITY ASSURANCE, HEALTH CARE; REFERENCE VALUES; RETROSPECTIVE STUDIES; UNCERTAINTY;

EID: 84873725402     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.11.015     Document Type: Article

References (27)

1. Katzmann J.A., Clark R.J., Abraham R.S., Bryant S., Lymp J.F., Bradwell A.R., et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002, 48(9):1437-1444.
2. Morris K.L., Tate J.R., Gill D., Kennedy G., Wellwood J., Marlton P., et al. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Intern Med J 2007, 37(7):456-463.
3. Drayson M., Tang L.X., Drew R., Mead G.P., Carr-Smith H., Bradwell A.R. Serum free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001, 97(9):2900-2902.
4. Bradwell A.R., Carr-Smith H., Mead G.P., Harvey T., Drayson M. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003, 361:489-491.
5. Rajkumar S.V., Kyle R.A., Therneau T.M., Melton L.J., Bradwell A.R., Clark R.J., et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005, 106:812-817.
6. Dispenzieri A., Kyle R.A., Katzmann J.A., Therneau T.M., Larson D., Benson J., et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008, 111(2):785-789.
7. Snozek C.L., Katzmann J.A., Kyle R.A., Dispenzieri A., Larson D.R., Therneau T.M., et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008, 22:1933-1937.
8. Dispenzieri A., Kyle R., Merlini G., Miguel J.S., Ludwig H., Hajek R., et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009, 23:215-224.
9. Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol 2008, 141(4):413-422.
10. Charafeddine K.M., Jabbour M.N., Kadi R.H., Daher R.T. Extended use of serum free light chain as a biomarker in lymphoproliferative disorders - a comprehensive review. Am J Clin Pathol 2012, 137:890-897.
11. Daval S., Tridon A., Mazeron N., Ristori J.M., Evrard B. Risk of antigen excess in serum free light chain measurements. Clin Chem 2007, 53:1985-1986.
12. Bosmann M., Kössler J., Stolz H., Walter U., Knop S., Steigerwald U. Detection of serum free light chains: the problem with antigen excess. Clin Chem Lab Med 2010, 48(10):1419-1422.
13. Vercammen M., Meirlaen P., Broodtaerts L., Vande Broek I., Bossuyt X. Effect of sample dilution on serum free light chain concentration by immunonephelometric assay. Clin Chim Acta 2011, 412(19-20):1798-1804. [Epub 2011 Jun 29].
14. Abraham R.S., Charlesworth M.C., Owen B.A., Benson L.M., Katzmann J.A., Reeder C.B., et al. Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. Clin Chem 2002, 48:1805-1811.
15. Palladini G., Russo P., Bosoni T., Verga L., Sarais G., Lavatelli F., et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009, 55:499-504.
16. Tate J., Bazeley S., Sykes S., Mollee P. Quantitative serum free light chain assay-analytical issues. Clin Biochem Rev 2009, 30(3):131-140.
17. National Pathology Accreditation Advisory Council (NPAAC) Requirements for the estimation of measurement uncertainty 2007, Commonwealth of Australia, Australian Government Department of Health & Ageing, Canberra, [http://www.ag.gov.au/cca].
18. NORDTEST technical report 537: handbook for calculation of measurement uncertainty in environmental laboratories 2003, NORDTEST, [www.nordtest.org].
19. Eurolab Technical Report No.1/2007 Measurement uncertainty revisited: alternative approaches to uncertainty evaluation [accessed on July 8, 2012]. http://www.eurolab.org/documents/Technical_Report_Measurement_Uncertainty_2007.pdf.
20. Katzmann J.A., Snyder M.R., Rajkumar S.V., Kyle R.A., Therneau T.M., Benson J.T., et al. Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies. Clin Chem 2011, 57(12):1687-1692.
21. Hutchison C.A., Harding S., Hewins P., Mead G.P., Townsend J., Bradwell A.R., et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008, 3:1684-1690.
22. Abadie J.M., van Hoeven K.H., Wells J.M. Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis?. Am J Clin Pathol 2009, 131:166-171.
23. Levinson S.S. Polyclonal free light chain of Ig may interfere with interpretation of monoclonal free light chain {kappa}/{lambda} lambda ratio. Ann Clin Lab Sci 2010, 40:348-353.
24. Marshall G., Tate J., Mollee P. Borderline high serum free light chain {kappa}/{lambda} ratios are seen not only in dialysis patients but also in non-dialysis-dependent renal impairment and inflammatory states. Am J Clin Pathol 2009, 132:309.
25. Paiva B., Vidriales M.B., Cerveró J., Mateo G., Pérez J.J., Montalbán M.A., et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
26. Ladetto M., Pagliano G., Ferrero S., Cavallo F., Drandi D., Boi M., et al. Correlation between clinical outcome and disease kinetics by quantitative PCR in myeloma patients following post-transplant consolidation with bortezomib, thalidomide and dexamethasone. Blood 2009, 114:960. [ASH Annual Meeting, Abstract].
27. Paiva B., Martinez-Lopez J., Vidriales M.B., Mateos M.V., Montalban M.A., Fernandez-Redondo E., et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011, 29:1627-1633.